Nonalcoholic Fatty Liver Disease in Asia, Africa, and Middle East Region

Ong, Janus P.; Alswat, Khalid; Salehiniya, Hamid; El-Kassas, Mohamed

doi:10.1016/j.cld.2023.01.014

Cited by 4 publications

(8 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 If current trends continue, the prevalence of MASLD is expected to increase significantly in various world regions by 2030. 8 9 10…”

Section: Lay Summarymentioning

confidence: 99%

“…1 If current trends continue, the prevalence of MASLD is expected to increase significantly in various world regions by 2030. [8][9][10] The presence of at least one cardiometabolic risk factor from a list including overweight and obesity, type 2 diabetes mellitus (T2DM), hypertension, hypertriglyceridemia, and hypercholesterolemia, is necessary for considering MASLD, and is interrelated and could impact the patient survival. 2,3 However, each metabolic disorder has distinct characteristics, resulting in several subtypes of patients requiring a personalized and multidisciplinary approach.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

El-Kassas,

Awad,

Elbadry

et al. 2024

Semin Liver Dis

Self Cite

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, and accurate data on its epidemiology are limited in many geographical regions, making it challenging to provide proper care and implement effective national plans. To combat the increasing disease burden, screening and diagnosis must reach a significant number of high-risk subjects. Addressing MASLD as a healthcare challenge requires a multidisciplinary approach involving prevention, diagnosis, treatment, and care, with collaboration between multiple stakeholders in the healthcare system. This approach must be guided by national and global strategies, to be combined with efficient models of care developed through a bottom-up process. This review article highlights the pillars of the MASLD model of care, including screening, risk stratification, and establishing a clinical care pathway for management, in addition to discussing the impact of nomenclature change on the proposed model of care.

show abstract

“…1 If current trends continue, the prevalence of MASLD is expected to increase significantly in various world regions by 2030. 8 9 10…”

Section: Lay Summarymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

El-Kassas,

Awad,

Elbadry

et al. 2024

Semin Liver Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is widely accepted that nonalcoholic fatty liver disease (NAFLD) is the major contributor to chronic liver diseases globally, especially after significant efforts against viral hepatitis, namely hepatitis B virus (HBV) vaccination and hepatitis C virus (HCV) treatment by direct-acting antiviral agents (DAA) [ 1 ]. NAFLD is defined as steatosis in 5% of hepatocytes with no other causes of fatty liver [ 2 ]. Defining the fatty liver patients at risk of disease progression is helpful.…”

Section: Introductionmentioning

confidence: 99%

“…NAFLD prevalence increases at the same rate as the prevalence of obesity and type 2 diabetes mellitus (T2DM) worldwide [ 1 ]. Awareness of the NAFLD burden is important to show its effects on stopping disease progression [ 1 , 2 ]. NAFLD is a unique disease comprising a range of conditions extending from simple steatosis to steatohepatitis, fibrosis, and cirrhosis.…”

Section: Introductionmentioning

confidence: 99%

“…The prevalence of NAFLD worldwide among adults is reaching about 25–30% [ 1 ]. The distribution differs between countries and regions, as the Middle East has the highest prevalence (32%), followed by South America (30%), with the least figures coming from Africa (13%); nevertheless, in developed countries, where the incidence of NAFLD is also increasing due to the increasing prevalence of the MetS and obesity [ 1 , 2 ]. The sedentary lifestyle and the growing prevalence of diabetes mellitus (DM), obesity, and metabolic syndrome have worsened the epidemic of NAFLD worldwide—an estimated prevalence of approximately 25%, and it can be as high as 60% to 70% in patients with DM.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis

et al. 2023

Self Cite

View full text Add to dashboard Cite

For many years, we have faced the complications of viral hepatitis and alcohol-related liver diseases such as cirrhosis, decompensation, portal hypertension, and hepatocellular carcinoma (HCC). Recently, we have seen a dynamic change in the field of hepatology. With the significant achievements in eradicating the hepatitis C virus by direct-acting antiviral agents and the rising epidemic of obesity, diabetes mellitus, and metabolic syndrome, there is a paradigm shift in the leading cause of liver cirrhosis and cancer to nonalcoholic fatty liver disease (NAFLD). Current data highlight the rapidly rising incidence of NAFLD-related HCC worldwide and expose the unseen part of the iceberg. In this review, we aim to update knowledge about the pathogenesis of NAFLD-induced HCC, surveillance difficulties, and promising disease markers. Molecular biomarkers, for example, may become a promising cornerstone for risk-stratified surveillance, early detection, and treatment selection for NAFLD-related HCC. Physicians can offer personalized and tailor-made clinical decisions for this unique patient subgroup.

show abstract

Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time

El-Kassas,

Alswat,

Tharwat

et al. 2024

Journal of Hepatology

View full text Add to dashboard Cite

Nonalcoholic Fatty Liver Disease in Asia, Africa, and Middle East Region

Cited by 4 publications

References 58 publications

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis

Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time

Contact Info

Product

Resources

About